Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011;46:1167–85.

Article  CAS  PubMed  Google Scholar 

Holbro A, Passweg JR. Management of hemolytic anemia following allogeneic stem cell transplantation. Hematol Am Soc Hematol Educ Progr. 2015;2015:378–84.

Article  Google Scholar 

Yousuf R, Thalith NFA, Loong TY, Leong CF. Naturally occurring ‘enzyme only’ anti-E antibody: a rare occurrence. Bangladesh J Med Sci. 2019;18:818–9.

Article  Google Scholar 

Harrison J. The ‘naturally occurring’ anti‐E. Vox Sang. 1970;19:123–31.

CAS  PubMed  Google Scholar 

Young PP, Goodnough LT, Westervelt P, Diersio JF. Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:1305–10.

Article  CAS  PubMed  Google Scholar 

Franchini M, Gandini G, Aprili G. Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:1169–72.

Article  CAS  PubMed  Google Scholar 

Blin N, Traineau R, Houssin S, Peffault de Latour R, Petropoulou A, Robin M, et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant. 2010;16:1315–23.

Article  PubMed  Google Scholar 

Giraud C, Thibert JB, Desbrosses Y, Debiol B, Alsuliman T, Bardiaux L, et al. Transfusion dans l’autogreffe et l’allogreffe de cellules souches hématopoïétiques chez l’adulte et l’enfant: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull du Cancer. 2019;106:S52–8.

Article  Google Scholar 

Worel N, Böhm A, Rabitsch W, Leitner G, Mitterbauer M, Kalhs P, et al. Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning. Transfusion. 2012;52:1348–53.

Article  CAS  PubMed  Google Scholar 

Chan JYS, Tokessy M, Saidenberg E, Giulivi A, Tay J, Allan DS. Rh D alloimmunization in allogeneic HSCT. Bone Marrow Transplant. 2013;48:459–60.

Article  CAS  PubMed  Google Scholar 

Xhaard A, Bouton M, Delugin L, Giraud C, Guyon A, Giroux-Lathuile C, et al. [Transfusion management and immuno-hematological follow-up after allogeneic hematopoietic cell transplantation: recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull du Cancer. 2024;11;S78–83.

Bailén R, Kwon M, Pérez-Corral AM, Pascual C, Buño I, Balsalobre P, et al. Transient hemolysis due to anti-D and anti-A1 produced by engrafted donor’s lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation. Transfusion. 2017;57:2355–8.

Article  PubMed  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

Article  PubMed  PubMed Central  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.

CAS  PubMed  Google Scholar 

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389–401.e1.

Article  PubMed  Google Scholar 

Lin Y, Saskin A, Wells RA, Lenis M, Mamedov A, Callum J, et al. Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes. Vox Sang. 2017;112:79–86.

Article  CAS  PubMed  Google Scholar 

Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999;23:953–9.

Article  CAS  PubMed  Google Scholar 

Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;53:710–5.

Article  CAS  PubMed  Google Scholar 

Ortiz S, Orero MT, Javier K, Villegas C, Luna I, Pérez P, et al. Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome. Blood Transfus. 2017;15:472–7.

PubMed  PubMed Central  Google Scholar 

Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39:763–71.

Article  CAS  PubMed  Google Scholar 

Xhaard A, Miekoutima E, Pirenne F, François A, Tiberghien P, Sebert M, et al. The transfusion of non-prophylactically RH-KEL1 antigen-matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patients. Vox Sang. 2022;117:693–700.

Article  CAS  PubMed  Google Scholar 

Mielcarek M, Zaucha JM, Sandmaier B, Maloney D, Butrynski J, Maris M, et al. Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO incompatibility. Br J Haematol. 2002;116:500–1.

Article  PubMed  Google Scholar 

Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105:2973–8.

Article  CAS  PubMed  Google Scholar